OverviewWhat is 5-Amino-1MQ?
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a selective small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Although frequently categorized alongside research peptides, 5-Amino-1MQ is technically a small organic molecule rather than a peptide. NNMT catalyzes the methylation of nicotinamide (vitamin B3), a critical precursor for NAD+ biosynthesis. By inhibiting NNMT, 5-Amino-1MQ redirects nicotinamide toward the NAD+ salvage pathway, increasing intracellular NAD+ availability.[1]
Preclinical research has demonstrated that NNMT is significantly upregulated in metabolically dysfunctional tissues — particularly white adipose tissue and liver — in obese subjects. Pharmacological inhibition of NNMT with 5-Amino-1MQ has shown dose-dependent improvements in body weight, fat mass, glucose tolerance, and hepatic steatosis in diet-induced obesity models.[2]
ScienceMechanism of Action
The primary mechanism of 5-Amino-1MQ centers on disrupting NNMT’s role in depleting NAD+ precursors:
Normal NNMT Activity (Inhibited by 5-Amino-1MQ): NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine (SAH). This reaction diverts nicotinamide away from NAD+ synthesis and consumes methyl donors.[3]
Effect of NNMT Inhibition: Blocking this enzyme preserves nicotinamide for NAD+ biosynthesis via the salvage pathway, simultaneously increasing intracellular NAD+ levels and SAM availability. Elevated NAD+ activates NAD+-dependent sirtuins (SIRT1, SIRT3), which regulate mitochondrial biogenesis, fatty acid oxidation, and insulin signaling. Elevated SAM enhances histone methylation and polyamine flux, both of which contribute to adipose tissue remodeling and increased energy expenditure.[1, 3]
EvidenceKey Research Findings
Research FocusObesity & Metabolic Regulation
The strongest body of evidence for NNMT inhibition relates to obesity and metabolic dysfunction. In a landmark 2014 Nature study, Kraus et al. demonstrated that genetic NNMT knockdown in white adipose tissue and liver protected mice against diet-induced obesity, increased energy expenditure, and improved polyamine metabolism through elevated SAM.[3]
Building on this genetic validation, Neelakantan et al. (2018) showed that selective small-molecule NNMT inhibitors — including 5-Amino-1MQ — reversed established obesity in high-fat diet mice, reducing body weight and fat mass while improving glucose metabolism.[4] The most comprehensive pharmacological study to date (Babula et al., 2024) demonstrated that 5-Amino-1MQ dose-dependently limited body weight gain, improved insulin sensitivity, and reduced hepatic steatosis over 28 days in diet-induced obese mice, with excellent tissue distribution to metabolically active organs.[2]
Research FocusNAD+ Metabolism & Cellular Energy
NNMT inhibition intersects directly with the rapidly expanding field of NAD+ biology. By preserving nicotinamide for NAD+ synthesis, 5-Amino-1MQ addresses the same metabolic deficit targeted by NAD+ precursor supplements (NMN, NR) but through a fundamentally different mechanism — reducing NAD+ precursor consumption rather than increasing precursor supply.[3]
The resulting increase in intracellular NAD+ activates sirtuin-dependent pathways controlling mitochondrial oxidative phosphorylation, fatty acid oxidation, and adaptive stress responses. This mechanism is particularly relevant in tissues where NNMT is highly expressed and upregulated — white adipose tissue, liver, and skeletal muscle — which are primary targets for metabolic intervention.[5]
Research FocusAdipose Tissue Remodeling
Research by Jia et al. (2022) revealed that NNMT is dynamically regulated during beige adipogenesis in a depot-specific manner. Cold exposure — a potent stimulus for brown/beige fat activation — modulates NNMT expression differently across adipose depots, with corresponding changes in NAD+ content critical for thermogenic gene expression (UCP1, CIDEA) and mitochondrial biogenesis.[5]
These findings position NNMT as a metabolic switch controlling the balance between energy-storing white adipose tissue and energy-burning beige/brown adipose tissue — a central concept in modern obesity research.
OverviewSummary of Research
5-Amino-1MQ represents a mechanistically distinct approach to metabolic intervention through selective NNMT inhibition. Preclinical evidence from genetic knockout models and pharmacological studies consistently demonstrates that blocking NNMT activity increases NAD+ availability, activates sirtuin-dependent energy pathways, reduces adiposity, improves glucose metabolism, and attenuates hepatic steatosis.
The compound occupies a unique position at the intersection of NAD+ biology, obesity pharmacology, and adipose tissue remodeling research. While clinical translation remains in early stages — with no published human trials as of 2026 — the preclinical data package continues to strengthen, with the most comprehensive pharmacokinetic-pharmacodynamic characterization published in 2024. Key open questions include oral bioavailability optimization, long-term safety profiling, and identification of patient populations most likely to benefit from NNMT-targeted therapy.
Q&AFrequently Asked Questions
Is 5-Amino-1MQ a peptide?+
No. 5-Amino-1MQ is a small-molecule enzyme inhibitor, not a peptide. It is a synthetic organic compound that selectively inhibits NNMT. While often sold alongside research peptides due to overlapping customer interest in metabolic research, it has a distinct chemical structure and mechanism of action.
How does NNMT inhibition differ from NAD+ precursor supplementation?+
5-Amino-1MQ and NAD+ precursors (NMN, NR) both aim to increase cellular NAD+ levels but through different mechanisms. Precursors increase the supply of NAD+ building blocks, while NNMT inhibition reduces the enzymatic consumption of nicotinamide — preserving existing precursors for NAD+ synthesis. These approaches are mechanistically complementary.
What animal models have been used to study 5-Amino-1MQ?+
Research has primarily utilized diet-induced obesity (DIO) mouse models using C57BL/6J mice on high-fat diets, genetic NNMT knockout models (global and tissue-specific), cold-exposure models for beige adipogenesis studies, and in vitro primary adipocyte cultures for mechanistic work.
What is the evidence for safety in preclinical studies?+
Published studies report normalization of liver function markers (ALT, AST) and correction of ketone body abnormalities in treated animals, suggesting good hepatic tolerance at efficacious doses. However, long-term toxicology studies beyond 28 days have not been published, and human safety data is not yet available.
Are there clinical trials for NNMT inhibitors?+
As of 2026, no clinical trial data for 5-Amino-1MQ or other selective NNMT inhibitors has been published. The compound remains in preclinical development. Ridgeline Therapeutics, associated with key published studies, appears to be advancing the program toward clinical translation.
What tissues express the highest NNMT levels?+
NNMT is most highly expressed in liver and white adipose tissue, with significant expression in skeletal muscle. Expression is upregulated in obesity and metabolic dysfunction, making these tissues primary pharmacological targets for NNMT inhibition.